A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 3
662
about 5.5 years
18+
19 sites in CA, FL, LA +8
What this study is about
Researchers are testing whether pirtobrutinib, a treatment, is more effective than ibrutinib for people with CLL/SLL. The trial also tests if pirtobrutinib alone is effective in treating people with CLL/SLL who have not had previous treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ibrutinib
- 2.Take Pirtobrutinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ibrutinib, pirtobrutinib
oral (Oral Tablet), oral
Primary: Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (CRi), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 2, Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1
Secondary: Comparative Tolerability, Duration of Response (DOR), Event-Free Survival (EFS), IRC-assessed Progression-Free Survival (PFS), Investigator assessed Progression-Free Survival (PFS), Overall Survival (OS), Percentage of Participants Achieving DOR Part 2, Time to Next Treatment (TTNT)
Oncology